L Kappos

753 total citations
12 papers, 81 citations indexed

About

L Kappos is a scholar working on Pathology and Forensic Medicine, Ophthalmology and Small Animals. According to data from OpenAlex, L Kappos has authored 12 papers receiving a total of 81 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 3 papers in Ophthalmology and 2 papers in Small Animals. Recurrent topics in L Kappos's work include Multiple Sclerosis Research Studies (8 papers), Retinal and Optic Conditions (3 papers) and Cerebral Venous Sinus Thrombosis (2 papers). L Kappos is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Retinal and Optic Conditions (3 papers) and Cerebral Venous Sinus Thrombosis (2 papers). L Kappos collaborates with scholars based in Switzerland, Canada and Netherlands. L Kappos's co-authors include Robert Katamay, Selim Orgül, Matthias Mehling, Konstantin Gugleta, Asan Kochkorov, Josef Flammer, Jeannette Lechner‐Scott, H. Brunnschweiler, Chris H. Polman and P. O’Connor and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and Journal of Neuroimmunology.

In The Last Decade

L Kappos

12 papers receiving 76 citations

Peers

L Kappos

PFM

NEURO

OPHTH

RHEUM

Gauthier Calais France

Sebastian Lukas Switzerland

Teiichiro Miyazaki Japan

Laure Bottin France

Vivien Häußler Germany

J. Desblache France

Melissa Ortega United States

Paloma Menéndez-Valladares Spain

Loreta Marquez United States

Zoe Rimler United States

Gauthier Calais France

L Kappos

48 ×0.8

PFM

15 ×0.6

NEURO

11 ×0.4

OPHTH

10 ×0.5

RHEUM

18 ×1.3

Citations per year, relative to L Kappos L Kappos (= 1×) peers Gauthier Calais

Countries citing papers authored by L Kappos

Since Specialization

Citations

This map shows the geographic impact of L Kappos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Kappos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Kappos more than expected).

Fields of papers citing papers by L Kappos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Kappos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Kappos. The network helps show where L Kappos may publish in the future.

Co-authorship network of co-authors of L Kappos

This figure shows the co-authorship network connecting the top 25 collaborators of L Kappos. A scholar is included among the top collaborators of L Kappos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Kappos. L Kappos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Stüve, Olaf, HP Hartung, M. S. Freedman, et al.. (2014). Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 3(6). 754–755. 2 indexed citations

Antel, Jack P., Xavier Montalbán, P. O’Connor, et al.. (2012). Long-Term (7-Year) Data from a Phase 2 Extension Study of Fingolimod in Relapsing Multiple Sclerosis (P01.129). Neurology. 78(Meeting Abstracts 1). P01.129–P01.129. 6 indexed citations

Kappos, L, EW Radue, P. O’Connor, et al.. (2012). Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004). Neurology. 78(Meeting Abstracts 1). S41.004–S41.004. 10 indexed citations

Traboulsee, Anthony, Cristina Constantinescu, L Kappos, et al.. (2009). Impact of cumulative dose and time on magnetic resonance imaging and clinical outcomes during long-term treatment with subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: exploratory analyses. Multiple Sclerosis Journal. 15(9). 126–127. 2 indexed citations

Kochkorov, Asan, Konstantin Gugleta, Robert Katamay, et al.. (2009). Rigidity of Retinal Vessels in Patients with Multiple Sclerosis. Klinische Monatsblätter für Augenheilkunde. 226(4). 276–279. 11 indexed citations

Gugleta, Konstantin, Asan Kochkorov, Robert Katamay, et al.. (2009). Retinal Vessels in Patients with Multiple Sclerosis: Baseline Diameter and Response to Flicker Light Stimulation. Klinische Monatsblätter für Augenheilkunde. 226(4). 272–275. 6 indexed citations

Gugleta, Konstantin, Matthias Mehling, Asan Kochkorov, et al.. (2008). Pattern of Macular Thickness Changes Measured by Ocular Coherence Tomography in Patients with Multiple Sclerosis. Klinische Monatsblätter für Augenheilkunde. 225(5). 408–412. 16 indexed citations

Kühle, Jens, et al.. (2004). 8 year follow-up of the European study of Interferon beta-1b (EUSPMS) in secondary progressive MS. UCL Discovery (University College London). 3 indexed citations

Miller, D. H., C. Polman, Carlo Pozzilli, et al.. (1997). 4-31-17 MRI protocol for the European trial of beta interferon-1b in secondary progressive multiple sclerosis. Journal of the Neurological Sciences. 150. S251–S251. 2 indexed citations

10.

Huber, Stephany Cares, et al.. (1996). [Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland].. PubMed. 126(35). 1475–81. 4 indexed citations

11.

Lechner‐Scott, Jeannette, H. Brunnschweiler, & L Kappos. (1995). Is it possible to achieve cross-cultural european agreement in the assessment of neurological deficits? First experiences in the european interferon-beta 1B trial for secondary progressive MS. Journal of Neuroimmunology. 56-63. 42–42. 8 indexed citations

12.

Polman, Chris H., et al.. (1995). Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.. PubMed. 1 Suppl 1. S51–4. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact